Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database
European Journal of Cancer · 2024
DOI: 10.1016/j.ejca.2024.114261 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Laurent Mortier und 18 weiteren Autor:innen. Beteiligte Einrichtung: Lille University, INSERM U 1189, CHU de Lille, CARADERM network, Lille Cedex, France. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Merkel Cell, Skin Neoplasms, Databases, Factual. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck KGaA.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lille University, INSERM U 1189, CHU de Lille, CARADERM network, Lille Cedex, France.
- CHU Ambroise-Paré, Boulogne-Billancourt, France. Electronic address: astrid.blom@aphp.fr.
- Merck Santé S.A.S. an affiliate of Merck KGaA, Lyon, France.
- CHU de Tours, Hôpital Trousseau, Tours, France.
- Gustave Roussy et Université Paris-Saclay Villejuif, France.
- CHU de Nantes, Hôpital Hôtel-Dieu, Nantes, France.
Förderung
- Merck KGaA
Zitieren
APA
Mortier, L., Blom, A., van Hille, B., Samimi, M., Luciani, L., Cahuzac, C., Robert, C., Quereux, G., Maubec, E., Miotti, H., Maillard, C., Aubin, F., Lenormand, C., Solbes, M. N., Joly, P., Kachaner, I., Lebbé, C., Dutriaux, C., & Saiag, P. (2024). Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114261
Vancouver
Mortier L, Blom A, van Hille B, Samimi M, Luciani L, Cahuzac C, et al. Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114261
BibTeX
@article{Mortier2024,
author = {Mortier, Laurent and Blom, Astrid and van Hille, Benoît and Samimi, Mahtab and Luciani, Laura and Cahuzac, Capucine and Robert, Caroline and Quereux, Gaelle and Maubec, Eve and Miotti, Hakima and Maillard, Cathy and Aubin, François and Lenormand, Cédric and Solbes, Marie-Noëlle and Joly, Pascal and Kachaner, Isabelle and Lebbé, Céleste and Dutriaux, Caroline and Saiag, Philippe},
title = {Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database},
journal = {European Journal of Cancer},
year = {2024},
doi = {10.1016/j.ejca.2024.114261}
}
EUVIMED